Hypotension caused by therapeutic doses of venlafaxine: Case report and proposed pathophysiological mechanisms

Journal of Psychopharmacology

Volumn 22, Issue 2, 2008, Pages 214-216

  Alexandrino Silva, Clóvis ^a   Henrique, Fernando ^a   De Andrade, Arthur Guerra ^a,b   De Toledo Ferraz Alves, Tânia Corrêa ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hypertension; Hypotension; Pathophysiological mechanisms; Therapeutic doses; Venlafaxine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CYTOCHROME P450 2D6; FLUOXETINE; VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; HYPOTENSION; MAJOR DEPRESSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOTENSION; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 40049091974     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107076403     Document Type: Article

References (14)

1. Banham N D G (1998) Fatal venlafaxine overdose [letter]. Med J Aust 169: 445, 448
2. Blythe D., Hackett L.P. (1999) Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 18: 309 - 313
3. Degner D., Grohmann R., Kropp S., Ruther E., Bender S., Engel R.R., Schmidt L.G. (2004) Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 37 (Suppl. 1). S39 - 45
4. Dorne J.L. (2004) Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam Clin Pharmacol 18: 609 - 620
5. Flordellis C., Manolis A.S., Scheinin M., Paris H. (2004) Clinical and pharmacological significance of α2-adrenoceptor polymorphisms in cardiovascular diseases. Int J Cardiol 97: 367 - 372
6. Grasmäder K., Verwohlt P.L., Rietschel M., Dragicevic A., Müller M., Hiemke C., Freymann N., Zobel A., Maier W., Rao M.L. (2004) Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 60: 329 - 336
7. Harvey A., Rudolph R.L., Preskorn S.H. (2000) Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57: 503 - 509
8. Johnson E.M., Whyte E., Mulsant B.H., Pollock B.G., Weber E., Begley A.E., Reynolds C.F. (2006) Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 14: 796 - 802
9. Kokan L., Dart R.C. (1996) Life-threatening hypotension from venlafaxine overdose. Annals of Emergency Medicine 27: 815
10. Letsas K., Korantzopoulos P., Pappas L., Evangelou D., Efremidis M., Kardaras F. (2006) QT interval prolongation associated with venlafaxine administration. Int J Cardiol 109: 116 - 117
11. Mazur J.E., Doty J.D., Krygiel A.S. (2003) Fatality related to a 30-g venlafaxine overdose. Pharmacotherapy 23: 1668 - 1672
12. Reznik I., Rosen Y., Rosen B. (1999) An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms. J Psychopharmacol 13: 193 - 195
13. Shams M E E, Arneth B., Hiemke C., Dragicevic A., Müller M.J., Kaiser R., Lackner K., Härtter S. (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31: 493 - 502
14. Thase M.E. (1998) Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59: 502 - 508